



Conditions for Applicants

GSK Africa Open Lab call for applications Nov 2023 – Jan 2024

The application process

- Applications must be completed in English.
- Applications will only be accepted via the application portal.
- The closing date will be 29th January 2024 5pm GMT. Applications received after this time will not be considered.
- Each applicant can only submit one application.
- Multiple applications with different investigators can be submitted by a single institution.
- Applications must be for work programmes that are lawful in the country in which the work will be carried out.
- Applications must not be submitted for research which would infringe the intellectual property rights of other parties.

Selection

- The outcome of the selection of funded proposals will be final, binding and not open to appeal.

What the grant offers

- The grant can be used to fund direct costs related to the project only, which includes costs for equipment, field work and data collection, consumables and research assistance, travel to conferences, subsistence and conference fees.
- Costs for principal applicant's salary are **not** included in this grant as it is assumed that they hold a salaried position in their institution. The applicant may however request a total of up to **5%** of their annual salary not exceeding **£5,000** for additional time expended on the project. This will be negotiated on a case-by-case basis with the institution involved.
- Institutional overhead costs will be paid at not exceeding **8%** of direct costs. The total award including overheads should not exceed £100,000
- The grant can only be used to deliver the objectives stated in the grant application.
- The grant may be used to contract out elements of the work where required; however, the grantee is not permitted to make sub-grants.
- Approved grants will have funds released in stages as required, in response to successful completion of prior stages of research and achievement of milestones.

Expectations of the grantee and institution

- The principal applicant's institution will be responsible for the receipt and administration of all funds.
- All costs must be reasonable and justified and will ultimately be awarded at the discretion of GSK.
- The maximum term of the grant is three years from the date of agreement being signed. There is no minimum term.
- Grants are made on the basis that the grantee commits to conduct all work to the relevant applicable global standard including but not limited to: Declaration of Helsinki, ICH GCP, ICH GMP and all locally relevant regulations.
- Grantees must maintain transparent, adequate records to track use of the funds provided and the results recorded from the research.
 - Grantees are expected to have a dissemination plan that includes sharing the findings with relevant stakeholders and to publish research findings in quality peer-reviewed journals.

We may not be able to fund you if: you, anyone associated with your grants, or your grant activities, are:

- the target of international sanctions.
- located in a country that is the target of international sanctions.

Permissions

- Applicants agree that GSK may share the personal information submitted by the applicants and all other information submitted in application proposals, with third parties globally in order to process and review the application to assess suitability for a grant.
- Applicants confirm that they have all required permissions from third parties (including the research institution where the proposed research may be carried out and the proposed local supervisor/mentor in the event of a successful application) in order to submit the information provided in support of the application.
- Depending on the intellectual contribution associated with the proposal, successful grantees will be expected to sign a collaboration agreement with GSK which will be based on the relevant Lambert Agreement (or similar), as described at <http://www.ipa.gov.uk/Lambert>, with the further intention that results of the collaboration are shared for the broader benefit of the research community.